These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11782220)

  • 1. Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study.
    Larsson LI
    Acta Ophthalmol Scand; 2001 Dec; 79(6):567-71. PubMed ID: 11782220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension.
    Larsson LI
    Acta Ophthalmol Scand; 2001 Apr; 79(2):125-8. PubMed ID: 11284748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension.
    Larsson LI
    Ophthalmology; 2001 Aug; 108(8):1439-44. PubMed ID: 11470697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension.
    Larsson LI
    J Glaucoma; 2001 Apr; 10(2):109-14. PubMed ID: 11316092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peak pressures: crossover study of timolol and latanoprost.
    Sihota R; Saxena R; Agarwal HC; Pandey RM; Gulati V
    Eur J Ophthalmol; 2003 Jul; 13(6):546-52. PubMed ID: 12948313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
    Aung T; Wong HT; Yip CC; Leong JY; Chan YH; Chew PT
    Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension.
    Susanna R; Giampani J; Borges AS; Vessani RM; Jordao ML
    Ophthalmology; 2001 Feb; 108(2):259-63. PubMed ID: 11158796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
    Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
    Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH; Feldman RM; Sheu WP;
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects.
    Mochizuki H; Itakura H; Yokoyama T; Takamatsu M; Kiuchi Y
    Jpn J Ophthalmol; 2010 Jul; 54(4):286-90. PubMed ID: 20700794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure.
    Lusky M; Ticho U; Glovinsky J; Weinberger D; Nesher R; Yassur Y; Melamed S
    Ophthalmology; 1997 Oct; 104(10):1720-4. PubMed ID: 9331215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma.
    Rulo AH; Greve EL; Geijssen HC; Hoyng PF
    Ophthalmology; 1996 Aug; 103(8):1276-82. PubMed ID: 8764799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol.
    Hedman K; Alm A
    Eur J Ophthalmol; 2000; 10(2):95-104. PubMed ID: 10887918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
    Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM
    Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
    Schachar RA; Raber S; Courtney R; Zhang M
    Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.